PExA offers a patented, non-invasive technology to collect biomarkers from the small airways of the lung via exhaled air. The method is used globally by universities, hospitals, pharmaceutical companies, CROs and government agencies in the US and Europe, among others – in research on asthma, COPD, lung cancer, occupational exposure and pharmacokinetics. The company's goal is to enable earlier diagnosis and screening of lung diseases. PExA was founded in 2014 and is headquartered in Gothenburg.

Quotes for PExA AB

Right Now

+/-
0.057
%
14,58%
Latest
0.448
High
0.502
Low
0.4
Volume
486 276
Turnover (SEK)
223 015
Market Value (MSEK)
52,0
Time (Latest trade)
2026-07-09 15:19

Board

CEO

  • Tomas Gustafsson

Chairperson of the Board

  • Claes Holmberg

Board

  • Anna-Carin Olin
  • Björn Dahlöf
  • Martin Malmström

Videos

Largest Owners

Name Capital % Votes % Date
Daniel Nilsson privat och genom närstående 19,85 19,25 2025-09-23
Avanza Pension 10,34 10,02 2026-06-26
Sven Christer Andersson 8,25 8,00 2026-06-26
Ola Hermansson 5,11 5,14 2026-06-26
Nordnet Pensionsförsäkring 3,33 3,23 2026-06-26
Per Berger 2,42 2,34 2026-06-26
Anna-Carin Olin 1,82 4,07 2026-06-26
Mikael Blihagen 1,74 1,69 2026-06-26
Patrick Svensson 1,24 1,20 2026-06-26
Jörgen Östling 1,15 1,11 2026-06-26
** Powered by Modular Finance

Insider trading

*Powered by Modular Finance

Key Numbers

*Compiled data from Millistream